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Summary 1992), and intracranial aneurysms (Chapman et al.
1992; van Dijk et al. 1995).
Recently the second gene for autosomal dominant poly- ADPKD is a genetically heterogeneous disease that
cystic kidney disease (ADPKD), located on chromosome can be caused by an alteration in at least three differ-
4q21-q22, has been cloned and characterized. The gene ent genes. In 85% of families, the disease is caused by
encodes an integral membrane protein, polycystin-2, a mutation in the PKD1 gene, located on chromosome
that shows amino acid similarity to the PKD1 gene prod- 16p13.3 (Reeders et al. 1985; Peters and Sandkuijl
uct and to the family of voltage-activated calcium (and 1992). The gene was identiﬁed in 1994, and the gene
sodium) channels. We have systematically screened the product, polycystin-1, is predicted to be a transmem-
gene for mutations by single-strand conformation–poly- brane protein involved in cell-cell or cell-matrix inter-
morphism analysis in 35 families with the second type action (The European Polycystic Kidney Disease Con-
of ADPKD and have identiﬁed 20 mutations. So far, sortium 1994; Hughes et al. 1995; The American
most mutations found seem to be unique and occur PKD1 Consortium 1995; The International Polycystic
throughout the gene, without any evidence of clustering. Kidney Disease Consortium 1995). Recently the
In addition to small deletions, insertions, and substitu- PKD2 gene, located on chromosome 4q21-q22 (Kim-
tions leading to premature translation stops, one amino berling et al. 1993; Peters et al. 1993), has been cloned
acid substitution and ﬁve possible splice-site mutations and characterized (Mochizuki et al. 1996). Mutations
have been found. These ﬁndings suggest that the ﬁrst in this gene are responsible for the disease in Ç15% of
step toward cyst formation in PKD2 patients is the loss the families (authors’ unpublished observation). The
of one functional copy of polycystin-2. gene consists of 15 exons with an open reading frame
of 2,904 bp and a 3 UTR of 2,086 bp (Mochizuki et
al. 1996). The PKD2 gene product, polycystin-2, is
Introduction
predicted to be an integral membrane protein with
six transmembrane domains and internal amino andAutosomal dominant polycystic kidney disease (ADPKD)
carboxy termini. Polycystin-2 shows Ç50% similarityis one of the most frequently inherited disorders, with
to 450 amino acids of polycystin-1 and its Caenorhab-an incidence of 1/1,000 individuals (Dalgaard 1957).
ditis elegans homologue ZK945.9 and to 270 residuesThe disease is mainly characterized by the formation
of a voltage-activated calcium channel (Mochizuki etand enlargement of multiple cysts in both kidneys, which
al. 1996). Only a few families have been reported incan lead to renal failure in adults. In addition, extrarenal
whom the ADPKD-causing mutation has not beenmanifestations can occur, including cysts in other organs
linked to either chromosome 4 or chromosome 16(such as the liver, pancreas, and spleen) (Milutinovic et
(Bogdanova et al. 1995; Daoust et al. 1995; de Al-al. 1980; Gabow 1990), hypertension (Florijn et al.
meida et al. 1995). A possible third gene, however,
has not been identiﬁed yet.
In addition to the genetic heterogeneity of ADPKD,Received February 13, 1997; accepted for publication June 6, 1997.
phenotypic variability has been observed (Parfrey et al.Address for correspondence and reprints: Dr. D.J.M. Peters, Sylvius
Laboratory, Department of Human Genetics, P.O. Box 9503, 2300 1990; Bear et al. 1992; Gabow et al. 1992; Ravine et
RA Leiden, The Netherlands. E-mail: d.peters@ruly46.medfac al. 1992). Individuals with the second type of ADPKD
.leidenuniv.nl
tend to show a milder clinical phenotype, compared with 1997 by The American Society of Human Genetics. All rights reserved.
0002-9297/97/6103-0013$02.00 individuals with a mutation in the PKD1 gene. At the
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time of diagnosis, usually at an older age, these patients SSCA
have fewer cysts and are less likely to have hypertension. Intronic primers were selected to amplify all exons
They show a slower progression toward renal failure and adjacent splice junction sites of the PKD2 gene (for
and have a longer life span. Nevertheless, ADPKD is primer sequences, see Hayashi et al., in press). Because
essentially similar in both groups of patients. of the size of the coding sequence of exon 1 (595 bp),
Now that the PKD2 gene is identiﬁed, we can search primers were selected to amplify three overlapping prod-
for mutations in individuals affected with the second ucts, of 248, 202, and 335 bp. Table 1 shows the primer
type of ADPKD. We have analyzed 35 families, using pairs and annealing temperatures used for ampliﬁcation,
SSCP analysis (SSCA). After screening Ç80% of the as well as the sizes of the PCR products. SSCA was
gene, we found mutations in 20 families. In addition to performed according to protocols, with modiﬁcations
disease-causing mutations, a polymorphism was de- described by Orita et al. (1989). Between 30 and 100
tected in exon 4. Further functional analysis of these ng genomic DNA of one affected individual per family
mutations will have to show how inactivation of one was ampliﬁed in a total volume of 15 ml, by use of 15
copy of the PKD2 gene leads to cyst formation. pmol primers (synthesized by Pharmacia), 0.2 mM each
of dGTP, dATP, and dTTP and 0.025 mM dCTP, 0.5
mCi a-32P-dCTP, 0.06 units Supertrouper polymerase
Subjects, Material, and Methods (HT Biotechnology), and two different types of PCR
buffers (Supertaq buffer [0.1 M Tris-HCl pH 9.0, 0.5
Family Selection and DNA isolation M KCl, 0.1% gelatin, 1.5 mM MgCl2, and 1% Triton
A total of 35 families with the second type of ADPKD X-100] and LR PCR buffer [0.5 M KCl, 0.1 M Tris-
were selected for mutation screening in the PKD2 gene. HCl pH 8.9, 2 mg BSA/ml, 0.1% gelatin, and 1–2 mM
For all families, clear evidence against linkage to chro- MgCl2]). The ampliﬁcation protocol used was denatur-
mosome 16 was obtained (Nørby and Schwartz 1990; ing for 2 min at 94C, followed by 30 cycles of 1 min
Ravine et al. 1992; Fossdal et al. 1993; Peters et al. 1993; at 94C, 2 min at annealing temperature (see table 1),
Bogdanova et al. 1995; Coto et al. 1995; Veldhuisen et and 1 min at 72C and then a ﬁnal extension for 9 min
al. 1996; authors’ unpublished observations). Linkage at 72C. The PCR products were diluted 1:5 in SSCA
to chromosome 4 was established by at least two—but, loading buffer (47.5% formamide, 15 mM EDTA,
in most families, more—informative CA-repeat markers 0.05% SDS, 0.05% xylene cyanole, and 0.05% brom-
around the PKD2 gene. Most of the asymptomatic at- phenol blue) and were denatured at 95C. The products
risk individuals participating in this study were exam- were separated on either 5% or 10% nondenaturing
ined by ultrasonography, according to the criteria de- polyacrylamide gels (49:1, acrylamide:bis-acrylamide)
scribed by Bear et al. (1984). Mutations were found in or 8% gels (29:1) with or without 10% glycerol at either
families collected in the Netherlands (PK5069, PK5197, room temperature or 4C. Most samples were analyzed
PK5179, PK5144, PK5118, PK5120, and PK5183), at four different conditions. The optimal conditions are
Spain (PK6526, PK6533, PK6534, and PK6537), Ice- shown in table 2. Depending on the PCR product and
land (PK9502), Denmark (PK1080), England (PK5414), the condition of the gel, electrophoresis at 4C was per-
Australia (PK5403 and PK5404), Bulgaria (PK7827, formed at 50 W for 2.5–4 h, and electrophoresis at
PK7852, and PK7808), and Belgium (PK5609). room temperature took place at 7–15 W for 15–20 h.
Several of these families have been described else- Gels were exposed to Kodak XAR5 ﬁlms. For samples
where: PK5069 (Peters et al. 1993; van Dijk et al. 1995; with an aberrantly migrating product, SSCA was per-
Veldhuisen et al. 1996); PK6526, PK6533, PK6534, and formed on all family members, to check segregation of
PK6537 (families 13, 14, 15, and 16, respectively, in the fragment with the disease. In the case of the missense
Coto et al. 1995); PK9502 (family F2 in Fossdal et al. mutation in exon 5 (family PK5403), 116 control chro-
1993; Peters et al. 1993); PK1080 (Nørby and Schwartz mosomes of unrelated individuals were screened by use
1990; Peters et al. 1993); PK5403 and PK5404 (pedi- of the same SSCA conditions, to investigate whether an
grees 2 and 5 respectively in Ravine et al. 1992); PK5403 aberrant pattern is caused by a polymorphism present in
(family 13868 in Peters et al. 1993); and PK7827 and the population. The control chromosomes were derived
PK7852 (Bogdanova et al. 1995). from 42 individuals obtained from CEPH (Weissenbach
DNA was isolated from either blood leukocytes or et al. 1992), 26 PKD2 patients (chromosomes not in
Epstein barr virus–transformed lymphocytes by use of phase with the PKD2 mutation), and 3 unaffected rela-
standard procedures (Breuning et al. 1990). DNA from tives.
one affected individual of each family was selected for
DNA SequencingSSCA. RNA was isolated from a lymphocyte cell line of
one affected individual of family PK9502 and from Sequencing was performed manually or with the Au-
tomated Laser Fluorescent DNA sequencer (ALF; Phar-blood leukocytes of several control individuals.
/ 9a35$$se03 08-28-97 18:03:35 ajhga UC-AJHG
549Veldhuisen et al.: Mutations in the PKD2 Gene
Table 1
Primer Pairs Used for SSCA and RT-PCR
Primer Sequence Product Size Annealing Temperature






























2 R exon2 TTAGTGCTGCTTTCCTCCATGAGT
3 R exon3 CGGGGGTGTCTAGGAAGAGCTG
4 R exon4 TTCAGTCTGGTTGCTGGGCT
a F Å forward primer in exon; IF Å forward primer in intron; R Å reverse primer in exon; and IR Å reverse primer in intron.
macia). Products for manual sequencing were obtained SSCA primers (table 1) with an M13 extension (CGA-
CGTTGTAAAACGACGGCCAGT) at the 5 end of theby PCR on genomic DNA, with SSCA primers (table
1). Forward and reverse cycle sequence reactions were forward primers and with a biotin label at the 5 end
of the reverse primers. To sequence the mutations inperformed by use of the Amplicycle Kit according to
manufacturer’s protocol (Perkin-Elmer), by use of the families PK6533 and PK6534, the PCR products were
cloned in a pGEM-T7 vector (Promega) and were se-PCR ampliﬁcation primers. Products for the ALF were
obtained by ampliﬁcation of genomic DNA by use of quenced with either biotinylated M13 master primer
Table 2
Optimal SSCA Conditions
Polyacrylamide Gel Glycerol Temperaturea Time Power
Exon (%) (%) ( C) (h) (W)
1 10 10 RT 15 12
2 10 10 RT 17 12
3 10 10 RT 15 12
4 8 10 RT 15 15
10 10 RT 15 15
5 8 10 RT 15 15
10 10 RT 15 15
6 5 10 RT 15 12
8 5 0 4 3 50
10 10 RT 20 15
12 5 0 4 3 50
10 10 RT 22 12
a RT Å room temperature.
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Table 3
Mutations in PKD2 Gene
Restriction Site
and Product Sizes
Family Exon Sequence Changea Codon Change (bp)
PK5069 1 ins C 534–538 Frameshift 180r212X XcmI creation (336r234/102)
PK9502 2 del 16 bp (596–12)r599 or (596–13)r598 Splice mutation
PK5609 2 sub GrA (709/1) Splice mutation
PK5197 3 sub ArG (71002) Splice mutation HpaII creationb
PK7827 4 sub CrT 916 R306X Eco571 creationb
PK7852 4 sub CrT 916 R306X Eco571 creationb
PK5179 4 ins C 972–973 Frameshift 325r340X AvaI creation (356r248/148)
PK5414 5 del C 1193 Frameshift 398r451X
PK6537 5 del AA 1194/1195 Frameshift 398r407X
PK5403 5 sub TrG 1240 W414G
PK6534 6 del T 1362–1363 Frameshift 455r460X
PK5144 6 del T 1443–1445 Frameshift 482r513X
PK6533 6 del T 1443–1445 Frameshift 482r513X
PK5404 6 sub GrT 1480 E494X
PK6526 8 sub CrG (1717-3) Splice mutation SacI creation (282r59/223)
PK5118 8 del C 1781–1782 Frameshift 594r609X CviRI creationb
PK5120 8 del C 1781–1782 Frameshift 594r609X CviRI creationb
PK1080 12 sub ArG (2241-2) Splice mutation
PK5183 12 sub CrA 2286 Y762X RsaI loss (106/115r121)
PK7808 12 sub CrA 2286 Y762X RsaI loss (106/115r121)
a ins Å insertion; del Å deletion; and sub Å substitution.
b Restriction enzyme creates a complex pattern on agarose gel.
and the M13 reverse primer or the biotinylated M13 each exon, SSCA was performed at four different condi-
tions. Only exon 1 has not been screened systematically,reverse primer with the M13 master primer. The PCR
products were puriﬁed by use of an Easyprep kit (Phar- because the PCR of most samples was hampered by the
GC richness of this exon. Nevertheless, one alterationmacia). Single-stranded fragments of biotinylated PCR
products were obtained by use of magnetic beads (Dyna- was found in this exon (family PK5069). In 20 (57%)
of the 35 families the mutation in the PKD2 gene wasbeads). The sequence reaction was performed with a
ﬂuorescent universal or reverse primer of the autoread identiﬁed and subsequently sequenced. The results are
listed in table 3. Most mutations found so far are uniquekit (Pharmacia). Each mutation was sequenced in at least
two affected individuals of a family. and dispersed over the entire gene, although four muta-
tions occurred in more than one family (ﬁg. 1 and table
Restriction Analysis 3). In families PK5118 and PK5120, which we expected
Digestion of puriﬁed nonradioactive PCR products to be related, a deletion of a C in exon 8 was found.
was performed in a total volume of 20 ml with 10 units However, two seemingly unrelated family pairs (in fami-
of enzyme (table 3) in 0.5–2 1 One-Phor-All buffer (10 lies PK5144 and PK6533 and in families PK5183 and1 [100 mM Tris-acetate pH 7.5, 100 mM magnesium PK7808) have the same mutation, in exon 6 and exon
acetate, and 500 mM potassium acetate]; Pharmacia), 12, respectively. These pairs of families do not originate
and separation was on a 2.5% agarose gel. The creation from the same countries, and haplotype analysis did not
of the CviRI site in exon 8 (families PK5118 and reveal a common haplotype (data not shown). Also, in
PK5120) could not be tested, because of a large number two Bulgarian families (PK7827 and PK7852), which
of CviRI sites in this sequence. The pattern, created by carry the same CrT substitution in exon 4, no common
digestion of the exon 4 PCR product with Eco57I (fami- haplotype was found.
lies PK7827 and PK7852) and by digestion of the exon
3 PCR product with HpaII (family PK5197), was too Truncating Mutations
complex to allow conﬁrmation of the mutations. The majority of the mutations found were small dele-
tions or insertions, resulting in a frameshift leading to
Results a premature translation stop (table 3). In seven families
(PK6537, PK5414, PK6534, PK6533, PK5144,We have screened 80% of the PKD2 gene (all exons
except exon 1) for mutations in 35 PKD2 patients. For PK5118, and PK5120) a deletion of a C, a T, or AA
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PK1080). The intronic positions of these mutations are
shown between brackets in table 3. In families PK1080,
PK5197, and PK6526 the intronic part of the well-con-
served splice-acceptor site (yAG-gt) (Padgett et al. 1986)
is changed by a base-pair substitution. In family PK5609
a base-pair substitution changes the second intronic base
pair of the well-conserved splice-donor site (ag-GT)
(Padgett et al. 1986). Segregation of the mutations with
ADPKD in these families was conﬁrmed by SSCA. Addi-
tionally, restriction analysis of family PK6526 (exon 8)
by SacI showed segregation of the mutation with the
disease (data not shown). In family PK9502 a deletion
of 16 bp (either 12 intronic bp and 4 exonic bp or 13Figure 1 Model of polycystin-2, and localization of mutations.
The predicted protein has six transmembrane domains (range 5–8) intronic bp and 3 exonic bp) was found at the boundary
and intracellular amino and carboxy termini. The carboxy terminus of intron 1 and exon 2, disrupting the splice-acceptor
contains an EF-hand domain (shown as two small rods). Most of the site (table 3). Reverse-transcriptase PCRs (RT-PCRs)
alterations lead to premature stops, although several splice mutations
with forward primers in exon 1 and with reverse primers(*) and a missense mutation (**) are found. EX Å extracellular; and
in exons 2–4 (table 1) were performed on an affectedIN Å intracellular.
individual of family PK9502, who carries the 16-bp dele-
tion (individual not shown in ﬁg. 2), four control indi-
was found. In two families (PK5069 and PK5179) an viduals, and the cDNA clone cTM4, which contains part
insertion of a C caused the frameshift. A base-pair sub- of the PKD2 gene (Mochizuki et al. 1996). Products
stitution leading to a nonsense mutation was found in with the expected sizes were detected in all samples;
ﬁve families (PK7827, PK7852, PK5404, PK5183, and however, no aberrant spliced transcript was found in
PK7808). In all families, segregation of the mutation family PK9502 (data not shown). Segregation of the
with the disease was conﬁrmed by SSCA. deletion with ADPKD in family PK9502 was shown in
In several families the mutation causes the creation or 19 affected and 15 unaffected individuals of this family,
disruption of a restriction site (table 3). Most of these on a 10% polyacrylamide and 3% agarose gel (for anal-
mutations could be conﬁrmed by digestion with restric- ysis of part of the pedigree, see ﬁg. 2). Affected individ-
tion enzymes. In families PK7827 and PK7852 the non- ual PK9502-6 does not carry the deletion that was found
sense mutations in exon 4 created an Eco57I site, 13 bp in its affected family members. Absence of the mutation
downstream from an already existing Eco57I site. Since in this individual is in agreement with the haplotype
Eco57I cuts 16 bp downstream from its recognition site, analysis performed on this family (ﬁg. 2). A normal copy
only one of the two sites is recognized by the enzyme. of the gene was inherited because of a recombination
Restriction analysis did not show an aberrant pattern
event just proximal to the PKD2 gene. However, thesein affected individuals. The creation of a CviRI site in
ﬁndings are in conﬂict with the results obtained withaffected individuals of families PK5118 and PK5120
ultrasonography. When the individual was age 36 years,was not analyzed, because of a large number of CviRI
three cysts in the right kidney and many small cysts insites present in the PCR product of exon 8.
the left kidney were found.
Missense Mutation
Polymorphisms
In family PK5403 a missense variant was found,
In addition to disease-causing mutations, we identiﬁedchanging a tryptophan at codon 414 to a glycine (table
a polymorphism in exon 4. SSCA analysis of 43 unre-3). Segregation of the aberrant SSCA fragment with
lated individuals obtained from CEPH (Weissenbach etADPKD was conﬁrmed in this family (nine affected and
al. 1992) revealed that 47% of the individuals are het-seven unaffected individuals). Comparison of the se-
erozygous for this polymorphism, 23% are homozygousquence of polycystin-2 with that of polycystin-1 and
for one allele, and 30% are homozygous for the other.its Caenorhabditis elegans homologue (Mochizuki et al.
Sequencing of the exon 4 PCR product of several homo-1996) revealed that tryptophan is conserved between
zygous and heterozygous individuals did not reveal athe three predicted proteins. SSCA of exon 5 on 116
sequence difference in the coding part of the fragment,control chromosomes did not show the aberrantly mi-
so the polymorphism is most likely located within onegrating product. No restriction site disappeared or was
of the introns close to the boundary of exon 4.created by this mutation.
DiscussionSplice-Site Mutations
The pathways involved in cyst formation and otherFive mutations found are alterations of the splice sites
(families PK9502, PK5609, PK5197, PK6526, and symptoms in ADPKD patients are largely unknown.
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with either itself or other proteins, function as an ion
channel (Mochizuki et al. 1996).
In addition to functional studies, the spectrum of mu-
tations leading to ADPKD may provide insight into the
role of both proteins. The mutation detection for PKD1
is severely hampered by the repetitive nature of the gene.
Therefore, most mutations described thus far are trun-
cating mutations located in the unique part of the gene
(The European Polycystic Kidney Disease Consortium
1994; Peral et al. 1995, 1996a, 1996b; Turco et al.
1995; Neophytou et al. 1996; Roelfsema et al. 1996;
Rosetti et al. 1996). However, recently a number of
mutations have also been identiﬁed in the repeated part
of the gene, resulting in relatively short proteins that lack
the transmembrane and intracellular carboxy-terminal
parts (J. H. Roelfsema, personal communications).
Mutation detection of the PKD2 gene can provide
additional information about the mechanism involved
in cyst formation. To unravel the molecular defect in
patients with the second type of ADPKD, we performed
SSCA on 35 families. After screening a large part of
the open reading frame, we identiﬁed a mutation in 20
families. The undetected mutations in the remaining
families are either located in the unscreened coding part
of the gene (exon 1) or in intronic parts, or are notFigure 2 Segregation of a 16-bp deletion in a part of family
detected because of the limitations of SSCA. In addition,PK9502, on a 3% agarose gel. The haplotypes are shown for chromo-
linkage to chromosome 4 could not be established withsome 4 markers D4S1534, TMCA2, JV106, JSTG3, JSTG4, AICA1,
TMCA1, and D4S423. Deduced haplotypes are shown between square certainty in a few small families. Most mutations found
brackets. The PKD2 gene is located between JSTG4 and AICA1. The in PKD2 patients are unique and dispersed over the en-
16-bp deletion segregates with haplotype 3-1-3-3-4-4-4-1 (black bars) tire gene, although four mutations occur also in a second
in 19 family members (data shown for individuals 1, 2, 4, and 5).
family. The families from the Netherlands (PK5118 andOne affected individual (6), however, with a recombination event
PK5120) are most likely related. However, in the otherbetween JV106 and JSTG3, has not inherited the deletion from the
affected parent. Also, the child (7), who has inherited the same recom- family pairs no common haplotypes of markers ﬂanking
bined haplotype as the affected parent, does not carry the deletion. the PKD2 gene were found, suggesting three recurrent
Cysts were detected in both kidneys of individual 6; however, no mutations (data not shown). We detected one polymor-
ultrasound data were available for individual 7. For reasons of conﬁ-
phism in the PKD2 gene, with a heterozygosity of .47.dentiality, individuals are indicated by diamonds. Affected individuals
Since we did not see an alteration in the coding sequenceare represented by black symbols.
of this product (exon 4), the polymorphism is probably
located within one of the introns, close to the boundaries
of this exon.Mutations in at least two genes can cause essentially the
same disease. In most of the families the PKD1 gene is Fourteen (67%) of the mutations found are nonsense
mutations and frameshifts resulting in premature trans-mutated, and in Ç15% an alteration in the PKD2 gene
on chromosome 4q21-q22 is responsible for the disease. lation stops. Also, the three alterations of the PKD2 gene
originally described resulted in shorter proteins (Mochi-Both genes encode novel transmembrane proteins for
which the functions are unknown. The PKD1 gene prod- zuki et al. 1996). In family PK5069, where the mutated
gene has a translation stop before the ﬁrst predicteduct, polycystin-1, has a predicted role in cell-cell or cell-
matrix interactions (Hughes et al. 1995; The Interna- transmembrane domain, the translated protein of 212
amino acids is probably completely nonfunctional. Intional Polycystic Kidney Disease Consortium 1995). The
PKD2 gene product, polycystin-2, shows homology to the other PKD2 families premature stops were found in
exons 4–6, 8, and 12, suggesting that the domain(s)polycystin-1, but the predicted protein model lacks the
large extracellular N-terminal domain with associated essential for a normal protein function are located in
the carboxy-terminal part of the protein. For polycystin-motifs that has been described for polycystin-1 (Hughes
et al. 1995; Mochizuki et al. 1996). In addition, polycys- 2, an EF-hand domain has been described at the C-
terminus, which can be involved in the binding of cal-tin-2 shows homology to the family of voltage-activated
calcium (and sodium) channels and may, in association cium (Mochizuki et al. 1996). All mutations are located
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upstream of this domain, except for the exon 12 muta- kidneys in individual PK9502-6 are not caused by the
16-bp deletion, as is the case in the other affected familytion in families PK5183 and PK7808, which is located
within this domain. members, but are probably are caused by a de novo
mutation in one of the ADPKD genes or are due toIn addition to truncating mutations, we also identiﬁed
one missense mutation in exon 5 (family PK5403). The another cause.
Mutation analysis of the PKD2 gene by SSCA revealedalteration in family PK5403, where a T is replaced by
a G in the mutated gene, is found in eight affected indi- an alteration in 57% of the families after screening of
a large part of the gene. An equal amount of substitu-viduals of this family and is not observed in seven unaf-
fected individuals of this family. This alteration was ab- tions are found, compared with deletions and insertions.
However, whether this ratio is a correct representationsent in 116 control chromosomes. The mutation results
in the substitution of a glycine for a tryptophan at codon of PKD2 mutations in the population remains to be
seen. Deletions and insertions are more likely to cause414 of the protein. A tryptophan at this position is con-
served between polycystin-2, polycystin-1, and its C. conformational changes in a PCR product, which can
be detected by SSCA, than is the case for substitutions.elegans homologue. According to the predicted model
of the PKD2 gene product (ﬁg. 1), the substitution by a Other mutation-detection techniques are needed to iden-
tify the alterations in the remaining families. Since muta-glycine is located in the ﬁrst extracellular loop. Glycine,
which can adopt a much wider range of conformations tion in the PKD1 and PKD2 gene result in an essentially
similar phenotype, it is believed that the proteins arethan any other amino acid, may have an important effect
on the folding of this loop, resulting in a hampered involved in the same pathway. An in vitro study sug-
gested interaction between both transmembrane pro-protein function. Alternatively, the tryptophan-414
could be essential for interactions with other proteins. teins, via coiled-coil domains at the carboxy termini of
the proteins, although the coiled-coil domain predictedIn ﬁve families an alteration in the splice sites of exons
2, 3, 8, and 12 was found. In families PK6526, PK1080, for polycystin-2 is not perfect (Qian et al. 1997). For
both the PKD1 and PKD2 gene, truncating mutationsand PK5197 the splice-acceptor site is changed by an
intronic substitution, which cosegregates with the dis- have been found, resulting in loss of a large part of the
protein. These truncating mutations suggest thatease in the families (table 3). In family PK5609 the
splice-donor site is changed by a base-pair substitution. ADPKD is caused by a lack of normal functioning pro-
tein (i.e., haploinsufﬁciency), although the possibility ofWhether these splice mutations result in a premature
stop or in the skipping of (part of) an exon needs to a second somatic mutation in the normal copy of the
gene, as suggested for PKD1, cannot be excluded by ourbe established on transcript level. However, RNA of
affected individuals is not available yet. In family results (Reeders 1992; Qian et al. 1996). We have shown
that SSCA is an effective method to elucidate the pri-PK9502 the splice-acceptor site is disrupted because of
a deletion of 16 bp at the boundary of intron 1 and mary defect in PKD2 patients; however, functional stud-
ies have to show how mutations in the ADPKD genesexon 2. RT-PCRs with forward primers in exon 1 and
with reverse primers in exon 2–4 on cDNA of an af- lead to the inactivation of an unknown pathway.
fected and control individuals did not reveal an aberrant
transcript, although we did amplify the normal-size Acknowledgmentstranscript.
Splice-site mutations may result in several possible We are grateful to the families and their physicians for their
cooperation. The collaboration leading to the collection ofalterations of the transcript (reviewed in Krawczak et al.
families described here was initiated by the Concerted Action1992; Nakai and Sakamoto 1994; Berget 1995; Maquat
‘‘Towards Prevention of Renal Failure Caused by ADPKD,’’1996). Either one or more exons are spliced out of the
funded by the European Community. We wish to thank S.transcript, introns are retained in the transcript, or an
Forrest and M. A. Mourik for the collection of families, Dr.alternative splice-acceptor site is used. Alternatively, the
M. Bo¨dvarsson for the clinical analysis of the Icelandic family,transcript could be unstable. So, deletion of one or more
R. Plug for ALF sequencing, L. Spruit for her assistance in
primer-adhesion sites, a large distance between the PCR family analysis, and J. H. Roelfsema for his help with the
primers, or absence of the transcript could explain the ﬁgures. This work was supported by funding from Dutch Kid-
incapability to amplify the aberrant product. In the same ney Foundation grant C-93.1324, National Institute of Health
family, one affected individual (PK9502-6) does not grant DK48383, and American Heart Association grant
have the 16-bp deletion detected in other family mem- 94015510.
bers, which is in concordance with the haplotype analy-
sis but not with the ultrasound data (ﬁg. 2). Also, the Referenceschild (PK9502-7), who has inherited the recombined
chromosome, does not carry the deletion. However, no American PKD1 Consortium, The (1995) Analysis of the geno-
mic sequence for the autosomal dominant polycystic kidneyultrasound data on this child are available. Thus, cystic
/ 9a35$$se03 08-28-97 18:03:35 ajhga UC-AJHG
554 Am. J. Hum. Genet. 61:547–555, 1997
disease (PKD1) gene predicts the presence of a leucine-rich otte DC, Duley IT, Jones RH (1992) Factors affecting the
progression of renal disease in autosomal dominant polycys-repeat. Hum Mol Genet 4:575–582
Bear JC, McManamon P, Morgan J, Payne RH, Lewis H, tic kidney disease. Kidney Int 41:1311–1319
Hayashi T, Mochizuki T, Reynolds DM, Wu GQ, Cai Y,Gault MH, Churchill DN (1984) Age at clinical onset and
at ultrasonographic detection of adult polycystic kidney dis- Somlo S. Characterization of the exon structure of the poly-
cystic kidney disease 2 gene (PKD2). Genomics (in press)ease: data for genetic counseling. Am J Med Genet 18:45–
53 Hughes J, Ward CJ, Peral B, Aspinwall R, Clark K, San Millan
JL, Gamble V, et al (1995) The polycystic kidney diseaseBear JC, Parfrey PS, Morgan JM, Martin CJ, Cramer BC
(1992) Autosomal dominant polycystic kidney disease: new 1 (PKD1) gene encodes a novel protein with multiple cell
recognition domains. Nat Genet 10:151–159information for genetic counselling. Am J Med Genet 43:
548–553 International Polycystic Kidney Disease Consortium, The
(1995) Polycystic kidney disease: the complete structure ofBerget SM (1995) Exon recognition in vertebrate splicing. J
Biol Chem 270:2411–2414 the PKD1 gene and its protein. Cell 81:289–298
Kimberling WJ, Kumar S, Gabow PA, Kenyon JB, ConnollyBogdanova N, Dworniczak B, Dragova D, Todorov V, Dimi-
trakov D, Kalinov K, Hallmayer J, et al (1995) Genetic CJ, Somlo S (1993) Autosomal dominant polycystic kidney
disease: localization of the second gene to chromosomeheterogeneity of polycystic kidney disease in Bulgaria. Hum
Genet 95:645–650 4q13-q23. Genomics 18:467–472
Krawczak M, Reiss J, Cooper DN (1992) The mutational spec-Breuning MH, Snijdewint FGM, Brunner H, Verwest A, IJdo
JW, Saris JJ, Dauwerse JG, et al (1990) Map of 16 polymor- trum of single base-pair substitutions in mRNA splice junc-
tions of human genes: causes and consequences. Hum Genetphic loci on the short arm of chromosome 16 close to the
polycystic kidney disease gene (PKD1). J Med Genet 27: 90:41–54
Maquat LE (1996) Defects in RNA splicing and the conse-603–613
Chapman AB, Rubinstein D, Hughes R, Stears JC, Earnest quence of shortened translational reading frames. Am J
Hum Genet 59:279–286MP, Johnson AM, Gabow PA, et al (1992) Intracranial an-
eurysms in autosomal dominant polycystic kidney disease. Milutinovic J, Fialkow PJ, Rudd TG, Agodoa LY, Phillips
LA, Bryant JI (1980) Liver cysts in patients with autosomalN Engl J Med 327:916–920
Coto E, Sanz de Castro S, Aguado S, Alvarez J, Arias M, dominant polycystic kidney disease. Am J Med 68:741–744
Mochizuki T, Wu G, Hayashi T, Xenophontos SL, VeldhuisenMenendez MJ, Lopez-Larrea (1995) DNA microsatellite
analysis of families with autosomal dominant polycystic kid- B, Saris JJ, Reynolds DM, et al (1996) PKD2, a gene for
polycystic kidney disease that encodes an integral membraneney disease types 1 and 2: evaluation of clinical heterogene-
ity between both forms of the disease. J Med Genet 32:442– protein. Science 272:1339–1342
Nakai K, Sakamoto H (1994) Construction of a novel data-445
Dalgaard OZ (1957) Bilateral polycystic disease of the kid- base containing aberrant splicing mutations of mammalian
genes. Gene 141:171–177neys: a follow-up of two hundred and eighty-four patients
and their families. Acta Med Scand 328:1–255 Neophytou P, Constantinides R, Lazarou A, Pierides A, Con-
stantinou Deltas C (1996) Detection of a novel nonsenseDaoust MC, Reynolds DM, Bichet DG, Somlo S (1995) Evi-
dence for a third genetic locus for autosomal dominant poly- mutation and an intragenic polymorphism in the PKD1 gene
of a Cypriotic family with autosomal dominant polycysticcystic kidney disease. Genomics 25:733–736
de Almeida S, de Almeida E, Peters DJM, Pinto JR, Tavora I, kidney disease. Hum Genet 98:437–442
Nørby S, Schwartz M (1990) Possible locus for polycysticLavinha J, Breuning MH, et al (1995) Autosomal dominant
polycystic kidney disease: evidence for the existence of a kidney disease on chromosome 2. Lancet 1:323–324
Orita M, Suzuki Y, Sekiya T, Hayashi K (1989) Rapid andthird locus in a Portuguese family. Hum Genet 96:83–88
European Polycystic Kidney Disease Consortium, The (1994) sensitive detection of point mutations and DNA polymor-
phisms using the polymerase chain reaction. Genomics 5:The polycystic kidney disease 1 gene encodes a 14 kb tran-
script and lies within a duplicated region on chromosome 874–879
Padgett RA, Grabowski PJ, Konarska MM, Seiler S, Sharp PA16. Cell 77:881–894 Florijn KW, Saase van JLCM, Breun-
ing MH, Chang PC (1992) Autosomal dominant polycystic (1986) Splicing of messenger RNA precursors. Annu Rev
Biochem 55:1119–1150kidney disease and hypertension: a review. In: Breuning
MH, Devoto M, Romeo G (eds) Contributions to nephrol- Parfrey PS, Bear JC, Morgan J, Benvon C, Cramer BC, McMa-
namon PJ, Gault MH, et al (1990) The diagnosis and prog-ogy. Vol 97: Polycystic kidney disease. Karger, Basel, pp
71–92 nosis of autosomal dominant polycystic kidney disease. N
Engl J Med 323:1085–1090Fossdal R, Bodvarsson M, Asmundsson P, Ragnarsson J, Pe-
ters DJM, Breuning MH, Jensson O (1993) Icelandic fami- Peral B, Gamble V, San Millan JL, Strong C, Sloane-Stanley
J, Moreno F, Harris PC (1995) Splicing mutations of thelies with autosomal dominant polycystic kidney disease:
families unlinked to chromosome 16p13.3 revealed by link- polycystic kidney disease 1 (PKD1) gene induced by intronic
deletion. Hum Mol Genet 4:569–574age analysis. Hum Genet 91:609–613
Gabow PA (1990) Autosomal dominant polycystic kidney dis- Peral B, Ong ACM, San Millan JL, Gamble V, Rees L, Harris
PC (1996a) A stable, nonsense mutation associated with aease: more than a renal disease. Am J Kidney Dis 16:403–
413 case of infantile onset polycystic kidney disease 1 (PKD1).
Hum Mol Genet 5:539–542Gabow PA, Johnson AM, Kaehny WD, Kimberling WJ, Lez-
/ 9a35$$se03 08-28-97 18:03:35 ajhga UC-AJHG
555Veldhuisen et al.: Mutations in the PKD2 Gene
Peral B, San Millan JL, Ong ACM, Gamble V, Ward CJ, Strong phic DNA marker linked to adult polycystic kidney disease
on chromosome 16. Nature 317:542–544C, Harris PC (1996b) Screening the 3 region of the polycys-
Roelfsema JH, Breuning MH, The European Polycystic Kidneytic kidney disease 1 (PKD1) gene reveals six novel muta-
Disease Consortium (1996) The long walk toward the PKD1tions. Am J Hum Genet 58:86–96
gene. In: Grunfeld JP, et al (eds) Advances in nephrology.Peters DJM, Sandkuijl LA (1992) Genetic heterogeneity of
Vol 25. Mosby Year Book, St Louis, pp 131–145polycystic kidney disease in Europe. In: Breuning MH, De-
Rosetti S, Bresin G, Restagno G, Carbonara A, Corra S, Devoto M, Romeo G (eds) Contributions to nephrology. Vol
Prisco O, Franco Pignatti P, et al (1996) Autosomal domi-97: Polycystic kidney disease. Karger, Basel, pp 128–139
nant polycystic kidney disease (ADPKD) in an Italian familyPeters DJM, Spruit L, Saris JJ, Ravine D, Sandkuijl LA, Fossdal
carrying a novel nonsense mutation and two missenseR, Boersma J, et al (1993) Chromosome 4 localization of
changes in exon 44 and 45 of the PKD1 gene. Am J Meda second gene for autosomal dominant polycystic kidney
Genet 65:155–159disease. Nat Genet 5:359–362
Turco AE, Rosetti S, Bresin E, Corra S, Gammaro L, MaschioQian FJ, Germino FJ, Cai Y, Zhang X, Somlo S, Germino
G, Pignatti PF (1995) A novel nonsense mutation in the
GG (1997) PKD1 interacts with PKD2 through a probable
PKD1 gene (C3817T) is associated with autosomal domi-
coiled-coil domain. Nat Genet 16:179–183 nant polycystic kidney disease (ADPKD) in a large three-
Qian F, Watnick TJ, Onuchic LF, Germino GG (1996b) The generation Italian family. Hum Mol Genet 4:1331–1335
molecular basis of focal cyst formation in human autosomal van Dijk MA, Chang PC, Peters DJM, Breuning MH (1995)
dominant polycystic kidney disease. Cell 87:979–987 Intracranial aneurysms in polycystic kidney disease linked
Ravine D, Walker RG, Gibson RN, Forrest SM, Richards RI, to chromosome 4. J Am Soc Nephrol 6:1670–1673
Friend K, Shefﬁeld LJ, et al (1992) Phenotype and genotype Veldhuisen B, Breuning MH, Wesby-van Swaay E, Boersma
heterogeneity in autosomal dominant polycystic kidney dis- J, Peters DJM (1996) Analysis of a large family with the
ease. Lancet 340:1330–1333 second type of autosomal dominant polycystic kidney dis-
Reeders ST (1992) Multilocus polycystic disease. Nat Genet ease. Nephrol Dial Transplant 11 Suppl 6:13–17
1:235–237 Weissenbach J, Gyapay G, Dib C, Vignal A, Morissette J,
Reeders ST, Breuning MH, Davies KE, Nicholls RD, Jarman Millasseau P, Vaysseix G, et al (1992) A second-generation
AP, Higgs DR, Pearson PL, et al (1985) A highly polymor- linkage map of the human genome. Nature 359:794–801
/ 9a35$$se03 08-28-97 18:03:35 ajhga UC-AJHG
